Skip to main content

Table 2 Main outcomes of the efficient scenarios

From: Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting

Scenario

Scenario characteristicsa

Detected cancers at an early stage (I/II), %

Reduction in lung cancer mortality, %

Lung cancer deaths averted

Discounted life years gained

Interval cancer cases

Overdiagnosed cases

Overdiagnosis, %

Discounted total cost, million euro

Discounted additional costs vs no screening, million euro

Cost per life years gained vs no screening (uniform discounting), euro

Discounted cost per lung cancer death averted vs no screening, euro

ICER vs the previous efficient scenario, euro

Efficient scenarios based on the cost per life year gained ratio

Scenario 65

55-75-40-10-NELSON-VDT300-none

67.31

9.95

14,373

133,222

23,057

6733

9.48

10,892

2232

16,754

155,287

16,754

Scenario 60

55-75-40-10-NELSON-VDT400-V300

71.35

12.38

17,889

164,864

19,854

17,892

9.69

11,516

2855

17,321

159,625

19,707

Scenario 41

50-75-15-9-NELSON-VDT400-V300

72.39

11.90

37,075

362,039

43,331

32,183

17.78

29,456

7556

20,870

203,792

23,804

Efficient scenarios based on the cost per averted lung cancer death ratio

Scenario 65

55-75-40-10-NELSON-VDT300-none

67.31

9.95

14,373

133,222

23,057

6733

9.48

10,892

2232

16,754

155,287

155,287

Scenario 64

55-75-40-10-NELSON-VDT400-none

67.95

10.65

15,395

140,490

21,367

9184

11.73

11,057

2397

17,059

155,675

161,124

Scenario 60

55-75-40-10-NELSON-VDT400-V300

71.35

12.38

17,889

164,864

19,854

17,892

19.69

11,516

2855

17,321

159,625

184,009

Scenario 22

55-80-30-15-NELSON-VDT400-V300

70.95

12.80

29,165

260,807

32,071

33,473

21.76

18,846

5296

20,307

181,597

216,454

Scenario 41

50-75-15-9-NELSON-VDT400-V300

72.39

11.90

37,075

362,039

43,331

32,183

17.78

29,456

7556

20,870

203,792

285,630

  1. aScenarios are named ranging these values as follows: ”population selection criteria-nodule management protocol-threshold values for growth rate and nodule size”